Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2018 (2018), Article ID 1402824, 4 pages
https://doi.org/10.1155/2018/1402824
Review Article

Postmastectomy Radiation Therapy: Are We Ready to Individualize Radiation?

1Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA
2Hazelrig Salter Radiation Oncology Center, 1700 6th Ave South, Birmingham, AL 35249, USA
3The Kirklin Clinic at Acton Road, 2145 Bonner Way, Birmingham, AL 35243, USA

Correspondence should be addressed to Jennifer F. De Los Santos; ude.cmbau@sotnassoledj

Received 22 November 2017; Revised 12 January 2018; Accepted 15 January 2018; Published 1 March 2018

Academic Editor: Robert-Alain Toillon

Copyright © 2018 Ashlyn S. Everett et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA: A Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017. View at Publisher · View at Google Scholar
  2. M. Overgaard, P. S. Hansen, J. Overgaard et al., “Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy,” The New England Journal of Medicine, vol. 337, no. 14, pp. 949–955, 1997. View at Publisher · View at Google Scholar
  3. M. Overgaard, M.-B. Jensen, J. Overgaard et al., “Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial,” The Lancet, vol. 353, no. 9165, pp. 1641–1648, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Ragaz, I. A. Olivotto, K. S. Wilson, J. J. Spinelli, and R. Durand, “RESPONSE: Re: Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial,” JNCI: Journal of the National Cancer Institute, vol. 97, no. 15, pp. 1163-1164, 2005. View at Publisher · View at Google Scholar
  5. J. G. Bazan and J. R. White, “The Role of Postmastectomy Radiation Therapy in Patients With Breast Cancer Responding to Neoadjuvant Chemotherapy,” Seminars in Radiation Oncology, vol. 26, no. 1, pp. 51–58, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. S. A. Doggrell, “‘Simply stunning’ – trastuzumab in HER2-positive breast cancer,” Expert Opinion on Pharmacotherapy, vol. 7, no. 5, pp. 631–634, 2006. View at Publisher · View at Google Scholar
  7. N. G. Thaker, K. E. Hoffman, M. C. Stauder et al., “The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer,” SpringerPlus, vol. 4, no. 1, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. S. A. Eschrich, W. J. Fulp, Y. Pawitan et al., “Validation of a radiosensitivity molecular signature in breast cancer,” Clinical Cancer Research, vol. 18, no. 18, pp. 5134–5143, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. J. F. Torres-Roca, W. J. Fulp, J. J. Caudell et al., “Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer,” International Journal of Radiation Oncology • Biology • Physics, vol. 93, no. 3, pp. 631–638, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Kuhmann, D. Weichenhan, M. Rehli, C. Plass, P. Schmezer, and O. Popanda, “DNA methylation changes in cells regrowing after fractioned ionizing radiation,” Radiotherapy & Oncology, vol. 101, no. 1, pp. 116–121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Szyf, P. Pakneshan, and S. A. Rabbani, “DNA methylation and breast cancer,” Biochemical Pharmacology, vol. 68, no. 6, pp. 1187–1197, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Luzhna and O. Kovalchuk, “Modulation of DNA methylation levels sensitizes doxorubicin-resistant breast adenocarcinoma cells to radiation-induced apoptosis,” Biochemical and Biophysical Research Communications, vol. 392, no. 2, pp. 113–117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. A. R. Halvorsen, Å. Helland, T. Fleischer et al., “Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy,” International Journal of Cancer, vol. 135, no. 9, pp. 2085–2095, 2014. View at Publisher · View at Google Scholar
  14. M.-H. Tsai, J. A. Cook, G. V. R. Chandramouli et al., “Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation,” Cancer Research, vol. 67, no. 8, pp. 3845–3852, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. C. B. Westbury, J. S. Reis-Filho, T. Dexter et al., “Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-α (ERα) in response to therapeutic radiation,” The Journal of Pathology, vol. 219, no. 1, pp. 131–140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. N. A. Temiz, D. E. Donohue, A. Bacolla et al., “The somatic autosomal mutation matrix in cancer genomes,” Human Genetics, vol. 134, no. 8, pp. 851–864, 2015. View at Publisher · View at Google Scholar
  17. NCI, NCI Dictionary of Cancer Terms, germline mutation, Secondary NCI Dictionary of Cancer Terms, “germline mutation”, https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=46384, 2017.
  18. S. Damineni, V. R. Rao, S. Kumar et al., “Germline mutations of TP53 gene in breast cancer,” Tumor Biology, vol. 35, no. 9, pp. 9219–9227, 2014. View at Publisher · View at Google Scholar
  19. M. Hisada, J. E. Garber, C. Y. Fung, J. F. Fraumeni Jr., and F. P. Li, “Multiple primary cancers in families with Li-Fraumeni syndrome,” Journal of the National Cancer Institute, vol. 90, no. 8, pp. 606–611, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Y. Ho, G. Fan, D. P. Atencio et al., “Possession of ATM Sequence Variants as Predictor for Late Normal Tissue Responses in Breast Cancer Patients Treated With Radiotherapy,” International Journal of Radiation Oncology • Biology • Physics, vol. 69, no. 3, pp. 677–684, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. H. Mao, D. Wu, R. DelRosario, A. Castellanos, A. Balmain, and J. Perez-Losada, “Atm heterozygosity does not increase tumor susceptibility to ionizing radiation alone or in a p53 heterozygous background,” Oncogene, vol. 27, no. 51, pp. 6596–6600, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. C. M. Iannuzzi, D. P. Atencio, S. Green, R. G. Stock, and B. S. Rosenstein, “ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects,” International Journal of Radiation Oncology • Biology • Physics, vol. 52, no. 3, pp. 606–613, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. R. E. Anderson and N. L. Warner, “Ionizing Radiation and the Immune Response,” Advances in Immunology, vol. 24, no. C, pp. 215–335, 1976. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Deorukhkar and S. Krishnan, “Targeting inflammatory pathways for tumor radiosensitization,” Biochemical Pharmacology, vol. 80, no. 12, pp. 1904–1914, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Nanda, M. C. Liu, C. Yau, and et al., Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2, Chicago, IL, USA, ASCO 2017 edition, 2017.
  26. J. G. Scott, A. Berglund, M. J. Schell et al., “A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study,” The Lancet Oncology, 2016. View at Publisher · View at Google Scholar